9:00am – 9:05am Welcome Remarks by Dr. Ming-Ming Zhou
9:05am – 9:15am Introduction of DPS Diversity Initiative by the DPS-SPA Team
9:15am – 11:30am Lab Presentations
11:30am – 12:00pm Meet with Dr. Erik Lium, President of MSIP
12:00pm – 12:30pm Lunch Break
12:30pm – 1:30pm Poster Presentations
1:40pm - 2:25pm Keynote: Dr. Chiara Giannarelli
2:25pm - 2:35pm Closing Ceremony


Instructions: You can view the poster and listen to the corresponding introduction by opening the poster you want to view in a separate tab while you play the intro.

  1. 01. M. Carlini 1:28
  2. 02. C. Morel 1:01
  3. 03. A. Warren 0:47
  4. 04. D. Clarke 1:00
  5. 05. N. Zaware/C. Kim 0:54
  6. 06. S. Ramsey 1:09
  7. 07. M. Duffy 1:02
  8. 08. R. Malik 2:09
  9. 09. K. Hutchinson 1:00
  10. 10. A. Rodrigues 1:07
  11. 11. S. Yang/ A. Stone 1:36
  12. 12. E. Kropiwnicki 1:02
  13. 14. Y. Zhou 1:19
  14. 15. A. Chow 1:04
  15. 16. Y. Xiong 1:47
  16. 17. N. Zartorski 1:07
  17. 18. G. Zilberg 1:11
  18. 19. A. Lachmann 1:05
  19. 20. J. Ribeiro 1:22
  20. 21. E. Evangelista 1:00
  21. 22. M. Jeon 1:35
  22. 23. K. Jagodnik 1:04
  23. 24. A. Bailey 0:59
  24. 25. A. Bartal 1:01
  25. 26. M. Wojciechowicz 1:06
  26. 27. M. Kuleshov 1:04

This poll is no longer accepting votes

Please pick your Top 10 posters that will present at our retreat:


President of MSIP

Erik Lium, PhD, is the President of Mount Sinai Innovation Partners (MSIP) and Chief Commercial Innovation Officer of the Mount Sinai Health System. Dr. Lium is responsible for advancing Mount Sinai’s research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialization of Mount Sinai technologies, and fostering the development of start-ups to advance promising early-stage technologies. Under Dr. Lium’s leadership and through Mount Sinai’s expansive network of industry partnerships, and vast array of innovators in the fields of drugs, devices, diagnostics, and digital health, Mount Sinai has become a globally recognized leader in technology commercialization. Under his leadership, there has been a significant increase in the number of products brought to the patient population, as well as in Mount Sinai’s startup activity surrounding unmet needs in healthcare. Dr. Lium joined Mount Sinai as Vice President of MSIP in 2014 and was named Executive Vice President in 2018. Earlier, he held positions at the University of California, San Francisco (UCSF), including Assistant Vice Chancellor of Innovation, Technology and Alliances; UCSF Principal Investigator for the Bay Area National Science Foundation I-Corps node; and Assistant Vice Chancellor of Research. He also served as Founder and President of LabVelocity Inc., information services company focused on accelerating research and development in the life sciences. Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.


Assistant Professor, Medicine and Cardiology
Assistant Professor, Genetics, Genomics Sciences
and Immunology

“Single cell immunophenotyping reveals novel mechanisms of human atherosclerosis”

Dr. Chiara Giannarelli received her MD from the University of Pisa, Italy in 1999. She undertook residency and specialty training and completed her PhD from the University of Pisa. In 2008, she moved to the Mount Sinai School of Medicine where she completed her research training cardiovascular disease. In 2012, she was recruited as Instructor of Medicine, Cardiology and in 2014 she was promoted to Assistant Professor at the Icahn School of Medicine at Mount Sinai. She is also an Assistant Professor of Genetics and Genomic Science and she holds a Scientific Faculty Appointment at the Precision Immunology Institute. The Giannarelli laboratory integrate systems pharmacology and systems genetics with molecular biology and imaging to reveal new mechanisms of cardiovascular disease. Dr. Giannarelli is the first to identify the single-cell immune composition of human atherosclerosis and to identify new T cell alterations associated with clinical outcomes (i.e. stroke).